Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

125.50 +0.97 (+0.78%)
Streaming Delayed Price Updated: 1:04 PM EDT, May 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,590,335
Open 125.13
Bid (Size) 125.48 (2)
Ask (Size) 125.52 (3)
Prev. Close 124.53
Today's Range 124.55 - 126.61
52wk Range 99.14 - 133.10
Shares Outstanding 2,531,374,696
Dividend Yield 2.33%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Summit Therapeutics' Lung Cancer Therapy Ivonescimab Shows Improved Progression-Free Survival Versus Merck's Multi-Billion Keytruda In China Study
Summit Therapeutics shares dropped 27.3% to $7.94 in premarket trading Friday after a 272.1% surge on Thursday. The company announced Phase 3 HARMONi-2 trial results, where ivonescimab significantly... 
Via Benzinga
Smart Money Is Betting Big In MRK Options
Via Benzinga

Performance

YTD
+10.83%
+10.83%
1 Month
-1.18%
-1.18%
3 Month
-3.05%
-3.05%
6 Month
+23.20%
+23.20%
1 Year
+11.75%
+11.75%

More News

Read More
Surmodics Stock Rockets, But Merck Stock Little Moved, On Takeover Deals
Via Investor's Business Daily
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment of Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma
From Merck & Co., Inc.
Via Business Wire
MERCK & CO. INC. (NYSE:MRK) Reveals Intriguing Technical Aspects. Here's What You Need to Know.
Via Chartmill
Performance Comparison: Merck & Co And Competitors In Pharmaceuticals Industry
Via Benzinga
Merck to Acquire EyeBio
From Merck & Co., Inc.
Via Business Wire
No Memes, Ma’am! Try a Sensible Biotech Bet With CytomX Therapeutics Stock.
Via InvestorPlace
Merck Reportedly Nearing $1.3B Acquisition Of EyeBio To Expand Eye-Care Market Presence
Via Benzinga
Merck Announces Third-Quarter 2024 Dividend
From Merck & Co., Inc.
Via Business Wire
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Merck's Multi-Billion Cancer Drug Keytruda Aces Late-Stage Lung Cancer Study
Via Benzinga
Merck Announces Phase 3 KEYNOTE-522 Trial Met its Overall Survival (OS) Endpoint in Patients With High-Risk Early-Stage Triple Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
When you look at NYSE:MRK, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
Via Chartmill
AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report
Via Benzinga
S&P 500 Plays And One Dow Jones Giant Lead Five Stocks Near Buy Points
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Via Benzinga
Why Top 4% Biotech Stock, Merus, Just Catapulted To A Record High
Via Investor's Business Daily
Billionaire Ken Griffin Is Buying These Dividend Stocks Hand Over Fist. Should You?
Via The Motley Fool
Bargain Bin: 3 Cheap Stocks to Buy Before Memorial Day
Via InvestorPlace
Large Cap Biopharmaceuticals Performance
Via Talk Markets
5 Stocks Powering The Dow ETF Year To Date
Via Talk Markets
Topics ETFs Stocks
Exposures US Equities
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Storm Shelter: 7 Safe Haven Stocks to Batten Down the Hatches
Via InvestorPlace
Which Is The Best Investment For You? High Yield Pfizer Or Higher Growth Merck?
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.